Spontaneous Intracranial Hemorrhage In Patients Research Articles

Andexanet alfa therapy showed No increased rate of thromboembolic events in spontaneous intracranial hemorrhage patients: A multicenter electronic health record study

•Intracranial hemorrhage accounts for two out of every three major intracranial hemorrhages.•Systemic anticoagulation is routinely prescribed for prevention of cerebrovascular accidents.•The FDA approved Andexanet alfa to treat life-threatening bleeding.•Andexanet alfa relationship to outcomes requires further investigation.

Ischemic and hemorrhagic strokes in young adults: Comparison of functional outcomes and return to work after stroke

BackgroundFunctional recovery and return to work (RTW) after stroke are important rehabilitation goals that have significant impact on quality of life. Comparisons of functional outcomes and RTW between ischemic stroke (IS) and hemorrhagic stroke (HS), especially among young adults with stroke, have either been limited or yielded inconsistent results. We aimed to assess functional outcomes and ability to RTW in young adults with IS and HS, specifically primary spontaneous intracranial hemorrhage (SICH). MethodsYoung adults with IS or SICH aged 18–50-years-old were included. Outcome measures were modified Rankins score (mRS) on discharge and 3-months and RTW at 3-months after stroke. Good functional outcome was defined as an mRS of 0–2. ResultsWe included 459 patients (71.5% male) with a mean age of 43.3 ± 5.7 years, comprising 49.2% IS and 50.8% SICH. Patients with SICH were more likely to have unfavourable shifts in ordinal mRS on discharge (OR 7.52, CI 5.18–10.87, p < 0.001) and at 3-months (OR 6.41, CI 4.17–9.80, p < 0.001). Patients with IS more likely achieved good functional outcomes (80.2% vs. 51.8%, p < 0.001) and were able to RTW at 3-months (54.4% vs. 36.3%, p = 0.004). Among all stroke patients with good functional outcomes, one-third did not RTW at 3-months. Patients with longer length of hospitalisation and higher National Institutes of Health Stroke Scale (NIHSS) score on admission, especially in the domain categories of level of consciousness, vision, motor function, language and neglect, were less likely to RTW at 3-months. ConclusionPatients with IS were more likely to RTW when compared to SICH patients. Many young stroke patients did not RTW despite good functional outcomes. Further research should therefore address differences in prognosis and identify predictors that influence ability to RTW after stroke in the young adult population.

Abstract Number: LBA16 Does Intracranial Hemorrhage Associated with Tenecteplase Occur Exclusively Within the Stroke Burden?

Introduction As IV tenecteplase (TNK) is becoming an alternative to IV alteplase in acute ischemic stroke (AIS), establishing the incidence of intracranial hemorrhage (ICH) complications is important. Given the higher fibrin specificity of TNK as compared to alteplase, our aim was to distinguish hemorrhage within the stroke burden versus spontaneous ICH in patients with AIS with TNK‐associated ICH. Methods Retrospective chart review of patients presenting from February 2020 to January 2022 with anterior circulation AIS to our comprehensive stroke center who received TNK was performed to evaluate for associated ICH. ECASS‐3 criteria was used to define hemorrhagic transformation and ICH score was used for primary, spontaneous ICH. Fisher exact test statistic was used to evaluate for significant differences in ASPECTS score, medium versus versus large vessel occlusion, angiographic recanalization, IV eptifibatide use, pre‐morbid antiplatelet use, and association with symptomatic versus asymptomatic hemorrhage. A benchmark less than 5% symptomatic ICH incidence was set based on historical alteplase rates within our network. Social science statistics software was used for data analysis. Results Out of 77 subjects who received TNK, 20.7% (n = 16) developed ICH, 9.1% (n = 7) of which were symptomatic ICH with a temporally‐related increase in NIHSS of at least 4 or greater. Seven subjects (43.75%) were male. Mean age was 73.38 (95% CI 65.92, 80.83). Median initial NIHSS was 16, 95% CI [11.74, 21.51]. Median ASPECTS was 9, 95% CI [8.74, 9.89]. Two subjects developed spontaneous, primary ICH (n = 1 symptomatic ICH, n = 1 non‐symptomatic ICH) in the absence of hemorrhagic transformation of ischemic stroke. No significant difference between subjects with asymptomatic hemorrhage versus symptomatic hemorrhage was found when comparing ASPECTS &gt; = 7 versus &lt; 7 (Fisher value = 1), angiographic recanalization (Fisher value = 1), use of IV eptifibatide (Fisher value = 1), pre‐morbid antiplatelet use (Fisher value = 0.13), or medium vessel occlusion (Fisher value = ‐0.63). Conclusions Expected rates of hemorrhagic transformation were higher in tenecteplase than our historical benchmark rate for alteplase. Spontaneous hemorrhage unrelated to ischemic stroke area were seen in 2 subjects without known hematological disorders. Larger, prospective studies are needed to validate safety of tenecteplase in real world settings.

The emergent neurosurgical outcome of spontaneous intracranial hemorrhage in patients with chronic liver disease.

The influence of chronic liver disease (CLD) on emergent neurosurgical outcomes in patients with spontaneous intracerebral hemorrhage (ICH) remains unclear. CLD is usually associated with coagulopathy and thrombocytopenia, which contribute to a high rebleeding rate and poor prognosis after surgery. This study aimed to confirm the outcomes of spontaneous intracranial hemorrhage in patients with CLD after emergent neurosurgery. We reviewed the medical records of all patients with spontaneous ICH from February 2017 to February 2018 at the Buddhist Tzu Chi Hospital, Hualien, Taiwan. This study was approved by the Review Ethical Committee/Institutional Board Review of Hualien Buddhist Tzu Chi Hospital (IRB111-051-B). Patients with aneurysmal subarachnoid hemorrhage, tumors, arteriovenous malformations, and those younger than 18 years were excluded. Duplicate electrode medical records were also removed. Among the 117 enrolled patients, 29 had CLD and 88 did not. There were no significant differences in essential characteristics, comorbidities, biochemical profile, Glasgow coma scale (GCS) score at admission, or ICH sites. The length of hospital stay (LOS) and length of intensive care unit stay (LOICUS) are significantly longer in the CLD group (LOS: 20.8 vs. 13.5 days, P = 0.012; LOICUS: 11 vs. 5 days, P = 0.007). There was no significant difference in the mortality rate between the groups (31.8% vs. 28.4%, P = 0.655). The Wilcoxon rank-sum test for liver and coagulation profiles between survivors and the deceased revealed significant differences in the international normalized ratio (P = 0.02), including low platelet counts (P = 0.03) between survivors and the deceased. A multivariate analysis of mortality found that every 1 mL increase in ICH at admission increased the mortality rate by 3.9%, and every reduction in GCS at admission increased the mortality rate by 30.7%. In our subgroup analysis, we found that the length of ICU stay and LOS are significantly longer in patients with CLD who underwent emergent neurosurgery: 17.7 ± 9.9 days versus 7.59 ± 6.68 days, P = 0.002, and 27.1 ± 7.3 days versus 16.36 ± 9.08 days, P = 0.003, respectively. From our study's perspective, emergent neurosurgery is encouraged. However, there were more prolonged ICU and hospital stays. The mortality rate of patients with CLD who underwent emergent neurosurgery was not higher than that of patients without CLD.

A Single Center Retrospective Review of Long Term Outcomes in Spontaneous Intracranial Hemorrhage Patients Who Received Hyperosmolar Therapy (P7-7.001)

A Single Center Retrospective Review of Long Term Outcomes in Spontaneous Intracranial Hemorrhage Patients Who Received Hyperosmolar Therapy (P7-7.001)

Effect of desmopressin acetate on acute spontaneous intracranial hemorrhage in patients on antiplatelet therapy

PurposeTo evaluate the impact of desmopressin acetate (DDAVP) on poor outcomes, hematoma expansion, and adverse events in patients diagnosed with a non-traumatic, antiplatelet-associated intracranial hemorrhage (ICH). MethodsThis was a multicenter, retrospective, propensity-matched cohort study comparing DDAVP to control in patients diagnosed with a non-traumatic ICH previously on antiplatelet therapy. Notable exclusion criteria included admission to trauma service, subarachnoid hemorrhages, confounding coagulopathic factors, and hematoma evacuation. Poor outcome, defined as discharge to hospice or in-patient mortality, was the primary outcome. Secondary outcomes included intracranial hematoma expansion and occurrence of adverse events, which included hyponatremia and thromboembolic events. ResultsA total of 49 patients receiving DDAVP were compared to 107 controls in the unmatched cohort. Thirty-seven patients treated with DDAVP and 55 controls were included in the propensity-matched analysis, which was adjusted for age, ethnicity, history of diabetes, receipt of platelet transfusion, and thromboembolism prophylaxis. Poor outcome (16.2% DDAVP vs 29% control, p = 0.13), rates of hematoma expansion (11.8% DDAVP vs 11.1% control, p = 0.99), and adverse events (21.6% DDAVP vs 20% control, p = 0.99) were statistically similar between the matched groups. ConclusionsDDAVP administration in patients with spontaneous antiplatelet-associated ICH was not associated with a reduction in poor outcomes, hematoma expansion, or an increase in adverse events. Use of DDAVP in this patient population appears to be safe. Larger prospective studies are warranted to evaluate DDAVP utility in this patient population.

Surgical treatment of spontaneous intracranial hemorrhage in patients with cancer: Analysis of prognostic factors

BackgroundIntracranial hemorrhage (ICH) is the most common cerebrovascular event in patients with cancer. We sought to evaluate the outcomes of surgical treatment for ICH and to determine possible pre-operative outcome predictors. MethodsWe retrospectively reviewed surgical procedures for the treatment of ICH in patients with cancer. Analysis included clinical and radiological findings of the patients. Primary endpoints were survival and mortality in index hospitalization. ResultsNinety-four emergency neurosurgeries were performed for ICH in 88 different patients with cancer over ten years. 51 patients had chronic subdural hematomas (CSDH: 54.3%), 35 with intraparenchymal hemorrhage (37.2%), 6 with acute subdural hematoma (ASDH: 6.4%), and only 2 with epidural hemorrhages (2.1%). Median patient follow-up was 63 days (IQR = 482.2). 71 patients (75.5%) died at follow-up, with a median survival of 33 days. Overall 30-day mortality was 38.3%; 27.5% for patients with CSDH. Lower survival was associated to higher absolute leucocyte count (HR 1.06; 95%CI 1.04–1.09), higher aPTT ratio (HR 3.02; 95% CI 1.01–9.08), higher serum CRP (HR 1.01; 95%CI 1.01–1.01), and unresponsive pupils (each unresponsive pupil - HR 2.65; 95%CI 1.50–4.68). ConclusionOutcomes following surgical treatment of ICH in patients with cancer impose significant morbidity and mortality. Type of hematoma, altered pupillary reflexes, coagulopathies, and increased inflammatory response were predictors of mortality for any type of ICH.

Surgical treatment of spontaneous intracranial hemorrhage in patients with cancer

Introduction: Intracranial hemorrhage (ICH) is the most common cerebrovascular event in patients with cancer. We sought to evaluate the outcomes of surgical treatment for ICH and to determine possible pre-operative outcome predictors.&#x0D; Methods: We retrospectively reviewed surgical procedures for the treatment of ICH in patients with cancer. Analyses included clinical, laboratory, and radiological characteristics. Primary endpoints were survival and mortality in index hospitalization.&#x0D; Results: Ninety-four emergency neurosurgeries were performed for ICH in 88 different patients with cancer over ten years. 51 patients had chronic subdural hematomas (CSDH: 54.3%), 35 with intraparenchymal hemorrhage (37.2%), 6 with acute subdural hematoma (ASDH: 6.4%), and only 2 with epidural hemorrhages (2.1%). Median patient follow-up was 63 days (IQR=482.2). 71 patients (75.5%) died at follow-up, with a median survival of 33 days. Overall 30-day mortality was 38.3% and reached 27.5% in patients with CSDH. Lower survival was associated to higher absolute leucocyte count (HR 1.06; 95%CI 1.04-1.09), higher aPTT ratio (HR 3.02; 95% CI 1.01-9.08), higher serum CRP (HR 1.01; 95%CI 1.01-1.01), and unresponsive pupils (each unresponsive pupil - HR 2.65; 95%CI 1.50-4.68). Lower absolute platelet count was associated with a modest increase in survival rates (every 1000 platelets - HR 0.99; 95%CI 0.97-0.99).&#x0D; Conclusion: Outcomes following surgical treatment of ICH in patients with cancer impose significant morbidity and mortality. Altered pupillary reflexes, coagulopathies, and increased inflammatory response were predictors of mortality for any type of ICH. CSDH was the most common type of ICH and had higher mortality rates than non-oncologic patients.

Intracranial hemorrhage in critically ill patients hospitalized for COVID-19

In this study, we report three cases of spontaneous intracranial hemorrhage in patients who were initially hospitalized at our tertiary care center in Washington, DC with symptoms of COVID-19. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was diagnosed in all three patients, who were critically ill, requiring intubation and ventilatory support. During their protracted hospitalizations, subsequent imaging disclosed intracranial hemorrhages, including intracerebral and subarachnoid hemorrhages, in the context of anticoagulation and coagulopathy. We believe this is related to the tropism of SARS-CoV-2 to the endothelial lining of the cerebral vasculature via their angiotensin-converting enzyme (ACE) II receptors. Given our findings, we advocate heightened vigilance for intracerebral hemorrhage events, and scanning when practicable, in COVID-19 patients which have prolonged ventilatory support and depressed neurologic examinations.

Frailty and spontaneous intracerebral hemorrhage: Does the modified frailty index predict mortality?

ObjectiveThis study aims to elucidate the impact of frailty on spontaneous intracranial hemorrhage (SICH) patient outcomes in the United States. Patients and methodsThis is a single center retrospective chart review of all adult patients (≥18 years old) admitted with a primary diagnosis of SICH due to hypertension, amyloid angiopathy, and coagulopathy from 2014−2017. The studied variables included length of stay, age, sex, ICH score variables, medications, and frailty as measured by the modified Frailty Index (mFI). ResultsA total of 240 patients with 248 SICH were included in the analysis. In this study, mFI was not predictive of overall mortality (p = 0.12). To further investigate this issue, patients with ICH scores of 2 or 3 were separately analyzed to assess the impact of mFI on moderate ICH cases. However, mFI was also not associated with increased hospital mortality in moderate ICH cases (p = 0.812). In bivariate Spearman analysis, mFI significantly correlated with several outcome measures including modified Rankin Scale (MRS) at discharge (p = 0.01), but ICH score also correlated with these outcomes (p < 0.001). Although ICH & mFI scores were both predictive of MRS with linear regression, multivariate demonstrated that the ICH score was the only independent risk factor for MRS (p = 0.698, p < 0.001 respectively). ConclusionFrailty, as measured by the mFI, was not an independent risk factor for increased mortality or worse outcomes in SICH patients. This study does not support incorporating the mFI score for SICH patients for prognostication.

Subarachnoid Hemorrhage in Congenital Factor X Deficiency: A Case Study and Literature Review

Introduction: Inborn factor X deficiency (FXD) is a very rare (1: 500,000) hereditary coagulation disorder, which is characterized by clinical mani- festations including hematoma, epistaxis, menorrhagia, ecchymosis, and central nervous system (CNS) or gastrointestinal (GI) bleeding (depending on the zygosity). In homozygote patients, the risk of spontaneous intracranial hemorrhage (ICH) is high. Objectives: The aim of this investigation was to study and long-term follow-up of the patients with FXD and ICH. In addition, we investigated their frequent bleeding symptoms throughout their life and the results were compared with results of other studies. Patients and Methods: This study investigated 2 cases with spontaneous intracranial hemorrhage in patients with severe congenital (factor X) FX deficiency including a 3-year-old boy and a 1-month-old female neonate. The world literature was explored through the PubMed Medline and Scopus using appropriate and pertinent key words. Results: The Patients referred to the hematology department due to the neurological complications such as vomiting, unconsciousness, prolonged nasal bleeding for recent 12 hours. They had no familial history of spontaneous CNS bleeding. The blood coagulation test analysis indicated a pro- longed activated partial thromboplastin time (APTT) and also revealed a prolonged prothrombin time (PT) and the low levels of coagulation factor X implicating severe congenital FX deficiency. They followed up by our hematologists to prevent intracranial hemorrhage. Discussions: As one ICH patient whose PT and aPTT suggest a coagulation disorder secondary to vitamin K deficiency or coagulation factor deficiency, unresponsiveness to vitamin K therapy should be useful to take FX deficiency into consideration.

Predictors of Poor Outcome at Hospital Discharge Following a Spontaneous Intracerebral Hemorrhage

ABSTRACTIntroduction: Spontaneous intracranial hemorrhage (S-ICH) often leads to significant morbidity and mortality. Clinical scoring systems can predict the mortality and functional outcome after ICH (FUNC score). FOUR score is a recently developed coma scale that incorporates brainstem reflexes. We propose that the combination of FUNC and FOUR scores will be a better prognostic indicator than either FUNC or FOUR score alone for S-ICH patients. Methods: We conducted a retrospective chart review of all S-ICH patients (>18 years of age) from January 2008 to May 2010. ICH volume was calculated using the ABC/2 formula. FUNC (≤5 or >5) and FOUR (≤10 and >10) scores were calculated from admission data. Statistical analyses included chi-square test, positive predictive value, and relative risk assessment. Results: Total number of patients was 92. The mean age of presentation was 64.6 ± 15.6 years (range: 27–95 years). Male to female ratio was 1.6:1. Combined FUNC score ≤ 5 and FOUR score ≤ 10 (F2 score; 95%) had higher positive predictive value for mortality than either FUNC score ≤ 5 (82%) or FOUR score ≤ 10 (81%). Conclusions: The combination of the FUNC and the FOUR scoring system is a better prognostication indicator for S-ICH patients than either FUNC or FOUR score.

The Role of Chronic Alcohol Intake in Patients with Spontaneous Intracranial Hemorrhage: A Carbohydrate-Deficient Transferrin Study

Background and Purpose: Chronic alcohol intake is considered to be a risk factor for spontaneous intracranial hemorrhage (SICH). However, there is a lack of objective data in this field. The aim was to assess its role in hemorrhagic stroke objectively and to evaluate its correlation with the elevation of γ-glutamyltransferase (GGT) plasma levels. The reliability of patients’ anamnestic data concerning alcohol intake was also assessed. Methods: Laboratory assessment of the plasma carbohydrate-deficient transferrin (CDT) level was performed in 105 SICH patients and in a control group of 105 patients with dorsalgia. All patients were treated at the Clinic of Neurology, Faculty Hospital, Olomouc, Czech Republic. GGT plasma level values and anamnestic data concerning alcohol consumption were also analyzed. χ² tests were applied when assessing statistical significance. Results: The CDT test was positive in 25.7% of SICH patients versus 7.6% of control group subjects (p = 0.0008). GGT plasma levels were elevated in 44.4% of SICH patients with a positive CDT test versus 25.6% of patients with a negative one. The GGT test is not reliable in the detection of alcohol intake when compared with the CDT test (p = 0.71). Only 13.0% of SICH patients with a positive CDT test (subgroup 1) stated regular and high consumption of all types of alcoholic beverages. Another 26.1% of these patients stated regular daily consumption of more than 1 liter, and 47.8% of them stated less than 1 liter of beer, with uncertain data concerning wine and spirits intake. Thirteen percent of subgroup 1 patients denied alcohol consumption altogether. Conclusions: Chronic alcohol consumption is at least one of several risk factors in one fourth of SICH patients in the Olomouc region of the Czech Republic. The CDT test is the most sensitive method to diagnose chronic alcohol consumption, and it is superior to the examination of GGT and the evaluation of patients’ anamnestic data.

Is coagulopathic liver disease a factor in spontaneous cerebral hemorrhage?

Hepatic dysfunction is a common cause of thrombocytopenia and coagulopathy and has been reported as a causal factor in spontaneous intracranial hemorrhage. We attempt to define the prevalence of intracranial hemorrhage in patients with severe liver disease and coagulopathy. We retrospectively reviewed the medical records, CT, and MRI acquired between January 1996 and August 1999 of patients with liver disease and a coagulopathy admitted for nontraumatic acute mental status changes. In 138 CT and MR scans performed on the 100 patients described above, no cases of spontaneous intracranial bleeding were detected. Contrary to past reports, we find no instance of spontaneous intracranial hemorrhage in patients with coagulopathic liver disease presenting with acute mental status changes. Therefore, unless associated with trauma, spontaneous intracranial hemorrhage in coagulopathic liver disease is very uncommon.

Intracranial Hemorrhage in Patients With Sickle Cell Disease-Reply

In Reply .—Drs Mallouh and Hamdan call attention to a particular clinical syndrome of posttransfusion hypertension, seizures, and intracranial hemorrhage which has been seen in patients with both thalassemia and sickle cell disease. The key factor in this syndrome appears to be the sudden onset of hypertension which leads to hypertensive encephalopathy and, about half of the time, to intracranial hemorrhage as well. The syndrome is distinctly different from the clinical events seen in our patients and discussed in our review. 1 Only one of our patients had been transfused, and neither patient was hypertensive at anytime. The transfused patient did have seizures, but they occurred before the exchange transfusion, concomitant with marked hyponatremia, and had been controlled for 48 hours before the intracranial hemorrhage occurred. As discussed in the review, we believe that spontaneous intracranial hemorrhage in patients with sickle cell disease is secondary to cerebral vasculopathy arising from